Johnson & Johnson Faces Patent Hurdles in Drug Business, Potentially Setting the Tone for Pharma Peers
![](https://www.mcalindenresearchpartners.com/wp-content/uploads/2023/04/laurynas-mereckas-1TL8AoEDj_c-unsplash-1024x683.jpg)
Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…
McAlinden Research PartnersApril 18, 2023